- The FDA and CDC resumed the rollout of the Johnson & Johnson COVID-19 vaccine, with a warning about rare blood clots.
- The CDC
identified 15 cases of a rare blood clotting condition called thrombosis with thrombocytopenia syndrome (TTS) in people who had received the J&J vaccine. - Millions of people have received the vaccine with no major side effects.
U.S. federal health officials said on April 23 that the Johnson & Johnson COVID-19 vaccine could restart, with vaccine fact sheets updated to warn of rare blood clot risks.
Several states moved quickly to resume their rollout of the one-dose vaccine.
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) acted shortly after the CDC’s independent vaccine advisory committee recommended lifting the pause.
“Together, both agencies have full confidence that this vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older,” acting FDA commissioner Dr. Janet Woodcock said in a media briefing on April 23.
Source: healthline